ABSTRACT The antigenic site recognized by a rat monoclonal antibody (clone YL 1/2) reacting with a-tubulin (Kilmartin, J. V., B. Wright, and C. Milstein, 1982, I. Cell Biol., 93:576-582) has been determined and partially characterized. YL 1/2 reacts specifically with the tyrosylated form of brain a-tubulin from different mammalian species. YL 1/2 reacts with the synthetic peptide Gly-(Glu)3-Gly-(Glu)2-Tyr, corresponding to the carboxyterminal amino acid sequence of tyrosylated t~-tubulin, but does not react with Gly-(Glu)3-Gly-(Glu)2, the constituent peptide of detyrosylated a-tubulin. Electron microscopy as well as direct and indirect immunofluorescence microscopy shows that YL 1/2 binds to the surface of microtubules polymerized in vitro and in vivo. Further in vitro studies show that the antibody has no effect on the rate and extent of microtubule polymerization, the stability of microtubules, and the incorporation of the microtubule-associated proteins (MAP2) and tau into microtubules. In vivo studies using Swiss 3T3 fibroblasts injected with YL 1/2 show that, when injected at low concentration (2 mg IgG/ml in the injection solution), the antibody binds to microtubules without changing their distribution in the cytoplasm. Injection of larger concentration of YL 1/2 (6 mg IgG/ml) induces the formation of microtubule bundles, and still higher concentrations cause the aggregation of microtubule bundles around the nucleus (>12 mg IgG/ml).
calmodulin (12) to microtubules have been shown respectively to inhibit polymerization (7) and to promote depolymerization (12) of microtubules in vitro, but it is not known whether they are relevant in vivo. Although the posttranslational modification of proteins is an important device in the regulation of protein function, nothing is known about the role played by the phosphorylation of B-tubulin (3, 21) and the detyrosylation of a-tubulin (28) in the polymerization and function of microtubules in vivo. With respect to the removal and incorporation of tyrosine into the carboxyterminus of atubulin, it would be important to locate this part of the tubulin molecule in the microtubule and to determine whether or not it is involved in the assembly and function of microtubules.
Here we report the characterization of a monoclonal antibody that specifically recognizes the tyrosylated form of atubulin. By using this antibody we have found the following: that the tyrosylated carboxyterminus of a-tubulin is (a) exposed on the surface of microtubules assembled in vitro and of cytoplasmic, spindle, and midbody microtubules polymerized in vivo, is (b) not involved in the polymerization of tubulin into microtubules, is (c) not part of the domains of tubulin binding MAP2 and tau, and (d) could play a yet unknown role in the normal distribution and organization of microtubules in the cytoplasm of interphase cells and in their function (32) . Portions of this work have been presented in abstract form (31) .
MATERIALS AND METHODS

Purification of Microtubule Protein and Studies on Micro-
tubules Polymerized In Vitro: Pig and rat brain microtubule protein were purified by two cycles of temperature-dependent polymerization-depolymerization (24) using buffer A (0.1 M MES, l mM MgCl2, 0.1 mM EGTA, 1 mM B-mercaptoethanol, l mM guanosine triphosphate, 0.2 mM phenylmethylsulfonyl fluoride, pH 6.75), and adding 30% glycerol in the first cycle of polymerization. Homogeneous tubulin, MAPs, and tau were prepared from microtubule protein as described (8, 22) .
All purified proteins were stored under liquid nitrogen. Studies on microtubule polymerization in vitro were performed using solutions of microtubule protein prepared in buffer A without pbenylmethyisulfonyl fluoride. Polymerization was induced by raising the temperature of the microtubule protein solution from 4"C to 37"C. The time course of microtubule polymerization was studied by continuously reading the turbidity developed at 350 nm using a Cary 15 spectrophotometer. The content of MAP2 and tau in microtubules was studied by measuring the MAPs and tau contained in microtubule pellets obtained from steady state microtubules polymerized using microtubule protein. Protein concentrations were estimated on SDS polyacrylamide gels using a microdensitometer (Joyce Loeble 3CS). The incorporation of MAP2 and tau into steady state microtubules polymerized using homogeneous tubulin was studied in a similar way (23) . The effects of the monoclonal YL 1/2 a-tubulin antibody on microtubule polymerization and stability, the content of MAPs and tau in microtubules, and binding of MAP2 and tau to microtubules were studied by preincubating different concentrations of antibody (see Results) with microtubule protein or purified tubulin at 4"C for 45 min before incubation at 37"C for 45 min or by polymerizing microtubule protein or purified tubulin to steady state for 45 min at 37"C before adding the antibody for another 45 min at 37"C.
Antibodies:
The rat monoclonal YL 1/2 and YOL 1/34 a-tubulin antibodies used in our studies were a gift of Dr. Kilmartin (Medical Research Council, Cambridge). Affinity-purified rat brain tubulin antibodies were obtained as previously described (36) . Rhodamine-conjugated goat anti-rabbit IgGs as well as rhodamine-and fluoresceine-conjugated goat anti-rat IgGs (Cappel Laboratories, Cochranville, PA) were purified by affinity chromatography using respectively rabbit IgG and rat lgG coupled to Sepharose 4B columns. Rhodamine-conjugated YL 1/2 antibodies containing 2 mol rhodamine/mole antibody were prepared using tetramethylrhodamine isothiocyanate as described (16) . Cleavage of YL 1/2 antibodies into Fab-fragments with mercuripapain (Worthington Biomedical) was performed as described (18) using a ratio of enzyme to IgG (wt/wt) of 1:600. Digestion was performed at 37"C for l h with an lgG concentration of 2 mg/ml, and cleavage products were separated on a Sephacryl S-300 column.
Antibody Probes: Approximately 15% of the total a-tubulin purified from brain is normally tyrosylated (17) , detyrosylated bovine brain microtubule protein was a gift of Dr. Kumar (National Institutes of Health) and was prepared as previously described (13) by treatment ofmicrotubule protein with pancreatic carboxypeptidase A. The octapeptide Gly-(Glu)3-Gly-(Glu)2-Tyr and the heptapeptide Gly-(Glu)3-Gly-(Gluh, constituents of the tyrosylated and detyrosylated carboxyterminus of a-tubulin, were synthesized by Penninsula Laboratories, Inc. (Belmont, CA) and were 69% (octapeptide) and 83% (heptapeptide) pure when examined by amino acid analysis.
Antibody-binding Studies: Immunoautoradiography oftyrosylated
and detyrosylated brain microtubule protein resolved into the a-and ~-tubulin subunits by SDS PAGE was performed as previously described (5) The fixed cytoskeletons were fnally treated with 1 mg/ml NaBH4 in PBS as described (29) . For specific removal of carboxyterminal tyrosine from a-tubulin the cytoskeletons were incubated with 10 gg/ml pancreatic carboxypeptidase A (Worthington Biomedical) in PBS for 30 min at 37"C and washed three times with PBS. Microinjection and indirect immunofluorescence microscopy were performed by procedures already described (30) using a Zeiss ICM 405 microscope. Cells were normally fixed and permeabilized with cold methanol (-20"C) for 5 min. For electron microscopy cells were grown in plastic dishes, fixed, and embedded in situ, and processed as previously described (35) .
For preabsorption experiments using indirect immunofluorescence microscopy, the peptides Gly-(Glu)rGly-(Glu)s or Gly-(Glu)3-Gly-(Glu)2-Tyr and either YL I/2 or YOL 1/34 antibodies were mixed in 0.1 M MES, pH 6.75, containing 10 mg/ml BSA at final concentrations of 10 #g lgG/ml and 0.5 mg peptide/ml. After being kept for 20 min at room temperature, 20 ul of each mixture were added to PtK2 cytoskeletons on circular 18-mm coverslips and indirect immunofluorescence microscopy was performed as described above.
RESULTS
Monoclonal YL I/2 Antibody Reacting with aTubulin Specifically Recognizes the Tyrosylated Form of the Protein
Two rat monoclonal antibodies (clones YL 1/2 and YOL 1/34) raised against yeast tubulin were shown to react specifically with a-tubulin (9). In the cell a-tubulin exists in two different forms, tyrosylated and detyrosylated (2, 15, 17, 19 ; see also reference 26), a-tubulin is translated as the tyrosylated form (28) .
Detyrosylation is performed by a specific carboxypeptidase that removes tyrosine from the carboxyterminus of the protein (1, 6, 10, 27; see also reference 13). The removed tyrosine is put back into the protein by the enzyme tubulin tyrosine ligase in a reaction requiring ATP (20; see also reference 4). Immunoautoradiography of bovine brain microtubule protein containing either tyrosylated or detyrosylated a-tubulin showed that the YL 1/2 antibody reacted exclusively with the tyrosylated form of a-tubulin (Fig. 1 , compare lanes 5 and 6). On the other hand YOL 1/34 antibody reacted with both tyrosylated and detyrosylated a-tubulin (Fig. 1, lanes 3 and   4) . 37"C, and of (b) steady state microtubules incubated with different concentrations of antibody at 37"C. The results of the sedimentation assay shown in Fig. 2 B demonstrated that tubulin polymerization was identical in preparations of microtubule protein preincubated with or without YL 1/2 at 4"C for 45 min before polymerization at 37"C. These results indicated that the antibody had no effect on the rate of microtubule nucleation and therefore that the tyrosylated carboxyterminus of a-tubulin was not required for the formation of microtubule nuclei. Studies on both the rate and extent of turbidity developed during microtubule polymerization revealed slight increases in samples incubated with the antibody. The increase was larger at higher concentrations of YL 1/2 ( Fig. 2A) . Because no differences in the critical tubulin concentration for polymerization were found between preparations of microtubule protein polymerized in the presence and absence of YL 1/2 (data not shown; see Fig. 2B ), the increases of the rate and extent of turbidity in the presence of YL 1/2 were probably due to coating of microtubules by antibody (see Fig. 3 b) . When microtubules polymerized in the presence and absence of antibody were cooled at 4"C, the turbidity decreased with identical rates to the initial basal levels (data not shown).
Studies on the Effects of YL 1[2 on Microtubule Polymerization and the Incorporation of MAP2 and Tau into Microtubules Assembled In Vitro
This result indicated that the antibody did not stabilize microtubules against cooling. Furthermore, microtubules polymerized in the absence and presence of YL 1/2 contained comparable amounts of MAP2 and tau (Fig. 2 B) , suggesting that the two MAP do not bind to the tyrosylated carboxyterminus of a-tubulin exposed on the surface of the microtubules (see below).
Location of the Tyrosylated Carboxyterminus of o~-Tubulin in Microtubules Polymerized In Vitro and In Vivo
To study the location of the tyrosylated carboxyterminus of a-tubulin in microtubules, we looked to the ability of YL 1/2 to bind to tubulin in microtubules polymerized both in vitro and in vivo.
We studied the ability of YL 1/2 to bind to tubulin in microtubules polymerized in vitro by measuring the antibody content of microtubule pellets obtained from preparations of (a) microtubule protein incubated with different concentrations of antibody at 4"C before raising the temperature to WEHLAND ET AL. 1-4) . The protein contained in the corresponding sample supernatants was similarly studied (lanes 5-8) . Sample incubated without YL 1/2 (lanes 1 and 5), and samples incubated with a molar ratio of tubulin/antibody of 2 (lanes 2 and 6), 1 (lanes 3 and 7), and 0. 2 (lanes 4 and 8) . LC, IgG-light chain; HC, IgG-heavy chain; T, tubulin. YL 1/2 was able to bind to tubulin in a concentrationdependent manner without affecting polymerization. Electron microscopy studies of microtubule pellets showed no aberrant polymerization and furthermore antibody coating of the microtubules polymerized in the presence of YL 1/2 (Fig. 3) . Identical results were obtained when steady state microtubules were incubated with different concentrations of antibody (not shown). These results indicated that the tyrosylated carboxyterminus of a-tubulin was located on the surface of microtubules polymerized in vitro.
A Monoclonal Antibody Specific for Tyrosylated ~-Tubulin
Indirect immunofluorescence microscopy studies using YL 1/2 showed that the tyrosylated carboxyterminus of a-tubulin was also located on the surface of cytoplasmic, midbody (Fig.  4,b and c') , and spindle microtubules (data not shown) as shown by the fluorescent labeling of these microtubules in cytoskeletons incubated with YL 1/2. The binding of YL 1/ 2 to the microtubules of cultured cells was prevented by preincubating the antibody with the synthetic peptide Gly-(Glu)3-Gly-(Glu)2-Tyr but not by preincubation with Gly-(Glu)3-Gly-(Glu)2 (data not shown). Gly-(Glu)3-Gly-(Glu)2-Tyr corresponds to the sequence of the eight last amino acids of the carboxyterminus of tyrosylated a-tubulin (17, 28) . Gly-(Glu)3-Gly-(Gluh is constituent of the carboxyterminus of detyrosylated a-tubulin. Neither peptide affected labeling of microtubules when preincubated with YOL 1/34. Furthermore the binding of YL 1/2 to microtubules was abolished by treating microtubule cytoskeletons with carboxypeptidase A (Fig. 4e') , an enzyme which selectively removed carboxyterminal tyrosine from a-tubulin (19) . As expected treatment of cytoskeletons with carboxypeptidase A did not affect the binding of YOL 1/34 (Fig. 4f') or the polyclonal tubulin antibody (Fig. 4, e and f ) to microtubules. Comparison of labeled microtubules using a mixture of YL 1/2 and polyclonal tubulin antibody as first antibodies in indirect immunofluorescence studies revealed identical numbers and patterns of microtubule distribution (Fig. 4, compare a and b) .
Effects of the Injection of YL 1/2 into Swiss 3T3 Fibroblasts on the Organization of Cytoplasmic Microtubules
Swiss 3T3 flbroblasts displayed microtubules stretching radially from the perinuclear centrosome to the plasma membrane (see uninjected cells in Fig. 5, b and e) . Injection of rhodamine-conjugated YL 1/2 into cells at a concentration of 2 mg IgG/ml in the injection solution resulted in binding of the antibody to microtubules without changing the distribution of microtubules in the cytoplasm (Fig. 5 h) . Injection of larger concentrations of rhodamine-conjugated YL 1/2 resulted in formation of microtubule bundles (6-12 mg IgG/ ml in the injection solution; Fig. 5, g and f) . Although unconjugated YL 1/2, when injected at low concentration (2 mg/ml), did not affect the normal distribution of microtubules in the cytoplasm by binding to microtubules (data not shown), unconjugated YL 1/2 at higher concentrations was more effective than rhodamine-conjugated YL 1/2 in promoting the aggregation of microtubule bundles around the nucleus (in Fig. 5, compare a withfand g ). On the other hand injected Fab-fragments of YL 1/2 remained diffusely distributed in the cytoplasm (data not shown), even when injected at high concentrations (10 mg/ml in the injection solution), i.e., microtubules were not decorated and their normal distribution remained unaffected when examined by double immunofluorescence. Even though Fab-fragments bound to microtubules when examined by indirect immunofluorescence (not shown), nonreactivity of microinjected Fab-fragments with microtubules might be due to a decreased affinity often found for Fab-fragments prepared from monoclonal antibodies.
After injection of YL 1/2 at intermediate concentrations (compare with Fig. 5g ), numerous microtubule bundles were revealed in injected cells by electron microscopy (Fig. 6) . At higher magnification the spacing between single microtubules in such bundles was not <20 nm (Fig. 6D) .
DISCUSSION
We have identified and partially characterized the antigenic site of a-tubulin reacting with the rat monoclonal YL 1/2 antibody raised against yeast tubulin (9). Studies on the ability of YL 1/2 to bind to tyrosylated and detyrosylated a-tubulin indicated that the antibody reacts specifically with tyrosylated a-tubulin. The primary structure of the antigenic site is not known in complete detail but probably related to the peptide Gly-(Glu)3-Gly-(Gluh-Tyr. This peptide constitutes the sequence of the eight last amino acids of the carboxyterminus of tyrosylated a-tubulin (18, 28) and reacts specifically with YL 1/2 as shown by preabsorption experiments.
With respect to this result it is important to note frequent antigenicity of the carboxyterminus of proteins and hydrophilic peptides (11). Both indirect immunofluorescence and electron microscopy studies of cytoskeletons and microtubules polymerized in vitro in the presence of YL 1/2 antibody, respectively, show that YL 1/2 binds to the surface of microtubules. Thus the carboxyterminus of a-tubulin is exposed on the microtubule surface. This location is in agreement with the removal of carboxyterminal tyrosine from a-tubulin in cytoskeletal microtubules by pancreatic carboxypeptidase A and further with the lack of effect of YL 1/2 on tubulin polymerization, a process requiring the interaction between tubulin domains presumably masked within the microtubule after polymerization.
We have also observed that YL 1/2 does not interfere with the binding of MAP2 or tau to microtubules in vitro. This result indicates that the tyrosylated carboxyterminus of atubulin is not part of the microtubule binding sites for MAP2 or tau and suggests that binding of MAP2 and tau to microtubules is not regulated by tyrosylation of a-tubulin.
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Although YL 1/2 has no effect on microtubule polymerization and stability, and the binding of MAP2 and tau to microtubules, it produces strong concentration-dependent changes in the distribution and function of microtubules when injected into cultured cells (see accompanying paper, reference 32). It is not clear whether or not the formation of microtubule bundles in cells injected with YL 1/2 is produced by the cross-linking of microtubules by the antibody. It is important to note in this respect that the lateral distance between the microtubules packed in the cell into bundles was not smaller than 20 nm. This distance is much larger than the largest distance possible between the two antigen binding sites of an IgG molecule (10-12 nm). Therefore it is possible that the binding of YL l/2 to the microtubule surface can instead interfere with the interaction of microtubules with unknown cell components required for the normal distribution of microtubules inside the cell. The collapse of microtubule bundles around the nucleus in cells injected with high concentrations of YL 1/2 could either result from formation of large bundles of microtubules or as indicated above from the antibody interfering in the interaction of other unknown cell components with the microtubules (see accompanying paper, reference 32).
